Skip to Content

Isatuximab-irfc (Sarclisa®) Regimens in 1q21 gain/amplification Relapsed/ Refractory Multiple Myeloma

Download PQI pdf 0.24MB

Last Updated: January 30, 2024

By: Jeanine Ewing, PharmD, BCOP | Chris Elder, PharmD, BCOP

About this PQI

The purpose of this PQI is to discuss the potential activity isatuximab-irfc (Sarclisa®)-based regimens have on patients with 1q21 gain or amplification (1q21+) relapsed, refractory multiple myeloma (MM) with or without other high-risk features.

More About This PQI

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI